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Introduction: Exacerbations of chronic obstructive pulmonary disease (COPD) 
have a huge impact on lung function, quality of life and mortality of patients. 
Emergency Department visits and hospitalizations due to exacerbations cause a 
significant economic burden on the health system. 
Objective: To describe the differences in the number of emergency visits and 
hospitalizations due to exacerbations of COPD among patients included in two 
models of care of the same institution. 
Materials and methods: A historical cohort study in which COPD patients who are 
users of two models of care were included: COPD integrated care program (CICP) 
and general consultation of pulmonology (GCP). The first model, unlike the second 
one, offers additional educational activities, 24/7 telephone service, and priority 
consultations. The number of emergency visits and hospitalizations due to COPD 
exacerbations in patients who had completed at least one year of follow-up was 
evaluated. The multivariable Poisson regression model was used for calculating 
the incidence rate (IR) and the incidence rate ratio (IRR) with an adjustment for 
confounding factors. 
Results: We included three hundred and sixteen COPD patients (166 from the 
CICP and 150 from the GCP). During the year of follow-up, the CICP patients had 
50% fewer emergency visits and hospitalizations than patients from the GCP (IRR: 
0.50, 95%CI: 0.29-0.87, p=0.014). 
Conclusions: COPD patients in the CICP had fewer emergency visits and 
hospitalizations due to exacerbations. Prospective clinical studies are required to 
confirm the results and to evaluate the factors that contribute to the differences. 
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Introducción. Las exacerbaciones de la enfermedad pulmonar obstructiva crónica 
(EPOC) tienen un gran impacto en la función pulmonar, la calidad de vida y la 
mortalidad de los pacientes. Las visitas al Departamento de Emergencias y las 
hospitalizaciones debido a las exacerbaciones causan una carga económica 
importante para el sistema de salud.  
Objetivo. Describir las diferencias en el número de visitas de emergencia y 
hospitalizaciones debidas a exacerbaciones de la EPOC entre los pacientes 
incluidos en dos modelos de atención de la misma institución.  
Materiales y métodos. Estudio de cohorte histórico en el que se incluyeron 
pacientes con EPOC que son usuarios de dos modelos de atención: el programa 
de atención integrada de la EPOC (CICP) y la consulta general de neumología 
(PCG). El primer modelo, a diferencia del segundo, ofrece actividades educativas 
adicionales, servicio telefónico 24/7 y consultas prioritarias. Se evaluó el número 
de visitas de emergencia y hospitalizaciones debido a exacerbaciones de la EPOC 
en pacientes que habían completado al menos un año de seguimiento. El modelo 
de regresión multivariable de Poisson se utilizó para calcular la tasa de incidencia 
(IR) y la razón de tasas de incidencia (IRR) con un ajuste para factores de 
confusión. 
Resultados. Se incluyeron trescientos dieciséis pacientes con EPOC (166 del 
CICP y 150 del PCG). Durante el año de seguimiento, los pacientes con CICP 
tuvieron un 50% menos de visitas de emergencia y hospitalizaciones que los 
pacientes con PCG (IRR: 0,50; IC del 95%: 0,29 a 0,87, p = 0,014). 
Conclusiones. Los pacientes con EPOC en el CICP tuvieron menos visitas de 
emergencia y hospitalizaciones debido a las exacerbaciones. Se requieren 
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estudios clínicos prospectivos para confirmar los resultados y evaluar los factores 
que contribuyen a las diferencias. 
Palabras clave: enfermedad pulmonar obstructiva crónica; brote de los síntomas; 
urgencias médicas; hospitalización; evaluación de programas y proyectos de 
salud; estudios de cohortes. 
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Chronic obstructive pulmonary disease (COPD) is a globally prevalent entity (1) 
with a high underdiagnosis rate (2); it is estimated that COPD will be the fifth 
world's leading cause of death by 2030 (3). In people older than 40 years, COPD 
has a prevalence of 14.5% in Latin America (4) and 8.9% in Colombia (5). It is 
generally caused by cigarette smoke (6,7), but in emerging countries, particularly in 
Colombia, exposure to wood smoke has a crucial etiological role (5,8). According 
to estimations of the National Administrative Department of Statistics of Colombia 
(DANE by its Spanish acronym), of the total deaths in the country in 2010, 4,500 
(2.25%) were due to respiratory diseases affecting the lower airways, secondary to 
tobacco consumption (9). 
COPD is frequently progressive and is not confined to the lungs, it also produces 
systemic manifestations (7,10). These characteristics frequently make COPD a 
disabling disease with a high individual, family, social and economic impact and 
have led, in the last two decades, to the creation of integrated care programs as a 
measure to improve the comprehensive care of patients (11). Integrated care and 
self-management programs have contributed to improve the quality of life and 
exercise capacity; and to reduce hospitalizations in COPD patients with moderate 
and severe obstruction (12). In the context of primary care, although some studies 
have shown an improvement in the quality of life (13), the impact of these 
programs has been less clear (14). In Europe, the management of COPD patients 
in an integrated care program showed a reduction in hospitalizations due to 
exacerbations in comparison with usual care (15-17). 
Exacerbations of COPD requiring hospital admission occur across all stages of 
airflow limitation and are a significant prognostic factor of reduced survival across 
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all COPD stages. Patients with COPD at a high risk for hospitalization can be 
identified by their past history for similar events (18). 
The present study was designed to evaluate the differences in the number of 
emergency visits and hospitalizations due to exacerbations in COPD patients from 
the same institution included in two models of care, one of them being an 
integrated care program. 
Materials and methods 
Design and collection of information 
Design and collection of information: We designed an analytical historical cohort 
study. We included COPD patients who were users of two models of care and 
were followed for at least one year: COPD integrated care program (CICP) and 
general consultation of pneumology (GCP). The two models belong to the same 
institution specialized in respiratory medicine (Fundación Neumológica 
Colombiana-FNC), located in Bogotá, which mainly serves patients of the 
contributory regimen in the national social security system (national health care 
system). The GCP started on 1992 and the CICP started on 2005. To allow 
comparability, only patients from the Plan Obligatorio de Salud (Obligatory Health 
Care Plan) (name in force during the time of data collection) who had completed at 
least one year of follow-up between 2011 and 2015 were included. The inclusion of 
patients was made for convenience, based on the completeness of the information 
(1 year of follow-up), until fulfilling the calculated sample. We reviewed the clinical 
records and institutional databases. The completeness of information referred only 
to a complete year of follow-up (patients having some missing information but 
having a complete year of follow-up were not excluded). The convenience 
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sampling of patients, including the requirement about the completeness of the 
information, worked equally for both groups (CICP and CGP) to decrease the risk 
of a disbalance between groups in this regard. Patients were assigned to the CICP 
or the CGP depending on the contracts of the insurers that pay for their care (some 
insurers pay for the CICP and others just pay for the GCP), such assignment 
remained unchanged during the study period for all recruited subjects. To 
compensate the risk of selection and confusion biases related with this method of 
assignment we used multivariable analysis (see further details in statistical 
analysis). Patients older than 40 years, having at least one year of follow-up, were 
enrolled and the diagnosis of COPD was confirmed by the verification of the 
postbronchodilator forced expiratory volume in one second (FEV1) over the forced 
vital capacity (FVC) ratio (FEV1/FVC) lower than 0.7 and a consistent history of 
exposure to a risk factor (smoking, wood smoke or occupation). 
The study was presented and approved by the ethics committee of the Fundación 
Neumológica Colombiana and was considered a research without risk according to 
Colombian regulations. 
Models of care 
Both the CICP and the GCP offer education, prevention, comprehensive treatment, 
and rehabilitation. Unlike the GCP, the CICP is interdisciplinary (pulmonologist, 
internist, respiratory therapist, psychologist and nutritionist), and offers additional 
educational activities (individualized reinforcement training in the use of inhalers, 
the importance of medication compliance, suggested nutrition and physical activity 
among others), 24/7 telephone service and priority consultations (made by 
pulmonologists that are performed on the same day the patient calls describing 
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deterioration of their respiratory condition). The characteristics of the medical 
consultation and the group of medical specialists who care the patients are similar. 
Patients receive an average of six consultations per pulmonologist in one year, six 
evaluations and educational activities per respiratory therapist, two consultations 
for nutrition, two consultations for psychology, medical consultations in need and 
permanent telephone support in case of doubts or decompensation. The 
prescription of physical activity and pulmonary rehabilitation, as well as the 
guidelines that guided pharmacological management were also similar in both 
groups (ALAT COPD Guideline [2011](19), Colombian COPD Guideline [2013](20) 
and GOLD Strategy [2011-2015](21). Patients are assigned to the CICP or the 
CGP depending on the contracts of the insurers that pay for their care, and this has 
a risk of selection bias that we seek to reduce through multivariable analysis. The 
patients in the GCP group could access the interdisciplinary team if the 
pulmonology makes an interconsultation. 
Measurements 
Information on demographic variables (sex, age, marital status) risk factors 
(tobacco use, wood smoke), respiratory symptoms, comorbidities (hypertension, 
diabetes, coronary heart disease, thromboembolic disease, congestive heart 
failure, sleep apnea, cancer),spirometry measurements (FEV1/FVC, FEV1) and six-
minute walk test (6MWT) was included during the year of follow-up. The type of 
pharmacological treatment was also recorded, use of short-acting bronchodilators, 
long-acting bronchodilators, inhaled steroids and phosphodiesterase inhibitors. The 
number of emergency visits and hospitalizations due to exacerbations of COPD 
was evaluated in patients who had completed at least one year of follow-up. 
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Definition of severity and exacerbations in COPD 
The severity of COPD was graded according to the Colombian Clinical Practice 
Guideline on COPD (20), which takes into account the degree of dyspnea, the 
degree of obstruction and the frequency of exacerbations or hospitalizations in the 
previous year. Exacerbations were defined as mild if they were managed on an 
outpatient basis only with adjustment of bronchodilator treatment; moderate if they 
required the use of systemic corticosteroids and/or antibiotics without the need for 
emergency visits or hospitalization; and severe if they required an emergency visit 
for more than 24 hours or admission (22). The emergency visits and 
hospitalizations were evaluated by self-report: in every follow-up consultation, 
patients were interrogated for the number of visits to the emergency room or 
hospitalizations, and this information was immediately recorded in the patient’s 
database (we did not use other institutions databases). 
Statistical analysis 
A sample size of 290 patients was calculated using the Whitehead algorithm (23) 
to determine sample sizes for comparing two counts of events, to detect an 
incidence rate ratio (IRR) of exacerbations of 0.7 (30% reduction in risk) by 
comparing the intervention group (CICP) versus the GCP in a Poisson regression 
model, with 80% power, 95% confidence (two-tailed) and an expected 
exacerbation rate of 0.89 per patient per year in the GCP (23,24). 
For continuous variables with normal distribution (according to the Kolmogorov-
Smirnov test) means and standard deviations were used, otherwise (non-normal 
distribution) medians and interquartile ranges were used. For categorical variables 
proportions were calculated, and comparisons were made using the Chi-square 
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test, evaluating their statistical significance. The p value for statistical significance 
was the same for all statistical analysis (p<0.05, two-tailed). 
For the analysis of the number of exacerbations according to their severity, the 
incidence rate (IR) per year (number of events/(person-years at risk)) was 
calculated for each model of care: CICP and GCP and an IR ratio (IRR) was 
measured. A Poisson multivariable regression model was used to compensate for 
potential selection and confusion biases related to the recruitment method 
(convenience sampling) and the observational nature of this study. The dependent 
variable of the Poisson regression model was the number of events, the exposure 
variable was the person-years at risk. For the offset variable, we used the 
“exposure” option included in Stata with the variable representing exposure 
(person-years at risk), in such case Stata takes the log of exposure (the offset 
variable represents the log of exposure). The potentially confounding variables 
assessed in our multivariable analyses included differences between both groups 
in COPD severity (COPD severity classification, severity of functional compromise 
and distance in six-minute walk test), medications influencing the risk of 
exacerbations (LABA, LAMA, corticosteroids, roflumilast, chronic oxygen therapy 
and pulmonary rehabilitation), demographic characteristics (body mass index, age, 
sex and marital status) and comorbidities (congestive heart failure, tobacco 
exposure, hypertension, diabetes, thromboembolic disease, sleep apnea and 
cancer). The severity of COPD was established according to the Colombian 
Clinical Practice Guideline on COPD (20), use of long-acting bronchodilators, use 
of inhaled corticoids and number of comorbidities. Bivariate analyses were 
performed looking for associations between potential confounders and the 
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intervention group and also for associations between such potential confounders 
and the dependent variables. Potential confounders included sociodemographic, 
clinical and treatment variables that, due to biological plausibility, could be 
associated with the intervention or with the effect. A p value < 0.2 was used to 
select potential confounders to be introduced in the multivariable models, such a p 
value was higher than the p value of 0.05, used for statistical significance (see 
above), as recommended (25), in order to avoid missing any confounding variable. 
Those variables that in the bivariate analyses were associated with a p < 0.2 with 
the intervention and the dependent variable under study and that were not 
mediator variables (26) were introduced into the multivariable model to build a 
saturated model. Afterwards, those variables not reaching a statistically significant 
association with the dependent variable (p>0.05) in the saturated model and that 
when eliminated did not significantly affect the regression coefficients or R2 were 
removed from the model, to leave it as parsimonious as possible. The statistical 
analysis was performed using SPSS statistical software version 22, Stata version 
11 and MedCalc version 16. 
Results 
Three hundred and sixteen 316 COPD patients, 166 from the CICP and 150 from 
the GCP were included. Table 1 shows the demographic and clinical 
characteristics of the participants. The mean age was similar in both groups, with a 
male proportion of 53.6% in CICP and 64.7% in GCP. The participants in the two 
groups were similarly distributed for the variables of active smoking, severity of 
functional compromise, value in liters and percentage of post-bronchodilator FEV1 
in spirometry, six-minute walk test, comorbidities and participation in pulmonary 
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rehabilitation programs. The follow-up time was of one year for all patients. The 
outcomes were the numbers of events (hospitalization, emergency room visits and 
exacerbation not requiring ER visit or hospitalizations). Such events had a Poisson 
distribution and their standard deviation values were lower than the mean values. 
Therefore, the best way of analyzing them was using Poisson regression. 
Significant differences were found in BMI, tobacco and biomass exposure, severity 
of COPD, post-bronchodilator FEV1/FVC ratio, concomitant congestive heart failure 
and treatment with chronic home oxygen treatment and long-acting bronchodilators 
(table 1). The post-bronchodilator FEV1/FVC ratio was 49.8% (±13) in the CICP 
group and 55.6% (±14.2) in the GCP group. The use of long-acting bronchodilators 
was more frequent in the CICP group than in the GCP, and chronic home oxygen 
treatment in the GCP group. The frequency of exacerbations by program is 
presented in the table 2, with median and interquartile range. 
After the adjustment by confounding variables, a lower number of severe 
exacerbations (those requiring emergency visits for more than 24 hours or 
hospitalizations) were found in the CICP group versus the GCP group (IR: 21.4 vs. 
42.7 per 100 person-years) with an IRR of 0.50 (95% CI: 0.29-0.87, p=0.014), 
which means a 50% reduction in the use of these health resources by CICP 
patients (Table 3). Similarly, the analysis of the emergency visits only showed a 
lower number in the CICP group versus the GCP group (IR: 9.7 vs. 20.7 per 100 
person-years, respectively); with an IRR of 0.47 (95% CI: 0.26-0.85; P=0.012), 
which means a 53% reduction in emergency visits in the CICP group (table 3).  
In contrast, a higher number of moderate exacerbations (were found in the CICP 
group versus the GCP group (IR: 63.3 vs. 17.3 per 100 person-years, respectively) 
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with an IRR of 3.65 (95% CI: 1.46-9.14, P=0.006) (Table 3). There were no 
differences between the groups for hospitalizations due to exacerbations (table 3). 
Other factors that were independently associated with an increased risk of 
exacerbations were a greater severity of COPD for all types of exacerbations 
(P<0.01). Long-acting bronchodilator use was associated with a lower risk of 
severe exacerbations (P<0.001) and the fact of being unmarried for severe 
exacerbations (P=0.019). Age, BMI, the presence of comorbidities and the risk 
factor for COPD (wood smoke vs. smoking) were not independently associated 
with the frequency of COPD exacerbations. The detailed results of the 
multivariable analysis with the variables included in the more parsimonious models 
are shown in the supplementary appendix. 
Discussion 
During the year of follow-up, CICP patients had 50% fewer severe exacerbations 
(IRR: 0.50, p: 0.014) and 53% fewer emergency visits (IRR: 0.47 p<0.012) in 
comparison with GCP patients, although the proportion of patients with severe 
COPD was higher in the CICP group. Given that the rate of mild plus moderate 
exacerbations was not significantly different between the CICP and GCP, and that 
the number of outpatient visits increased in CICP patients, it is possible that having 
24/7 telephone service and priority consultations to CICP patients may influence 
the lower number of emergency visits and hospitalizations in this group; but this 
requires a confirmatory prospective study. Although patients of both programs 
were routinely asked about exacerbations in every follow-up consultation and such 
data were immediately recorded, GCP patients had a less close follow-up, and that 
is one of the points to take into account to show the differences in results. 
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It has been previously documented that integrated care and self-management 
programs improve quality of life and exercise capacity and reduce hospitalizations 
in COPD patients with moderate and severe obstruction (12). Although integrated 
care also includes pulmonary rehabilitation programs whose benefits in exercise 
capacity, dyspnea and quality of life are equally well established, especially in 
patients with moderate and severe COPD (27,28), we believe that the additional 
components of the program play a role in the benefits obtained. In addition to the 
usual care and training, emphasis on self-management of the disease is made to 
COPD CICP patients in this study through additional educational activities; CICP 
patients are also provided with having 24/7 telephone service and priority 
consultations that are not possible through the GCP. 
In cases of exacerbation, CICP patients receive timely and intensive outpatient 
treatment, preventing the progression of the exacerbation, visits to emergency 
department and hospitalizations. This finding is related to what has been described 
in the United Kingdom, where rapid recognition and treatment improve recovery 
and reduce the risk of hospitalization (29). A recent study showed that a disease 
management program based on a multidisciplinary approach is useful in patients 
with impaired exercise capacity and little obstruction in spirometry (30). This 
reduction of emergency visits and hospitalizations is essential in the management 
of patients, not only because of its clinical impact at an individual level but also 
because of the significant reduction of care costs (16,17,31). 
Although in this study the proportion of patients receiving treatment with long-
acting bronchodilators was higher in the CICP group, the CICP intervention 
continued to be independently associated with a lower risk of severe exacerbations 
18 
 
after adjusting for this confounding variable in the Poisson multivariable regression 
model. However, this finding should be highlighted because in recent years the use 
of long-acting bronchodilators, alone (monotherapy) or in combination (double 
therapy), has become the first line of treatment, and its utility has been proven in 
improving symptoms and reducing exacerbations(7,32,33). 
More than 80% of the patients in the two groups of our study are treated with long-
acting bronchodilators. This behavior is not repeated in patients managed outside 
specialized institutions, which has been corroborated in Colombia, where the 
formulation of short-acting bronchodilators is still predominant (34). Although, the 
period of inclusion of patients for this study (2011 - 2015) precedes much of the 
information on long-acting bronchodilator treatment in COPD, the guidelines in 
force at that time already highlighted the role of anticholinergics and long-acting 
beta-agonists, indicating lack of adherence to national and international guidelines, 
mainly for administrative and cost reasons (lack of inclusion of drugs in the 
mandatory health plan). 
Other factors that may be related to the finding of fewer COPD exacerbations in 
CICP patients are not apparent. There were no significant differences between 
groups regarding age, comorbidities, and participation in pulmonary rehabilitation 
programs (includes exercises, energy saving activities, dance, Tai Chi, pre-
established educational workshops). There is not a clear explanation for the 
difference in exposure to tobacco and biomass (higher proportion of exposure to 
biomass in GCP patients), and it does not appear to have an impact on the 
difference in emergency visits and hospitalizations (the results were not modified 
when adjusted for this variable in the Poisson multivariable regression model). The 
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higher proportion of patients with severe COPD included in CICP can be 
understood because health insurers select this group of patients to refer them to a 
structured program in a specialized institution. It is expected that patients in a more 
severe condition will have a higher frequency of visits to emergency department 
and hospitalizations due to COPD exacerbations. In this study, there was a higher 
proportion of patients in a severe condition in CICP. The fact that CICP patients 
had fewer emergency visits and hospitalizations, despite their more severe 
disease, highlights the magnitude of the difference. 
The main limitation of this study is its historical cohort design. Recall bias may 
have affected outcomes, but it would be expected that the group with a less close 
follow-up (GCP) would have reported fewer exacerbations due to this bias, which 
would have harmed (instead of favoring) the results of the intervention. Both 
groups were equally treated regarding the requirement of including only patients 
having a complete year of follow-up, such requirement aimed at having 
comparable groups, we did not excluded patients with some missing information in 
their medical records. Therefore, we do not think that our study has an important 
risk of bias related to including only patients with complete medical records. This 
type of studies can be affected by confounding variables, although an extensive 
multivariable analysis was conducted (see the statistical analysis section and the 
supplementary appendix) to control for confounding variables, the effect of an 
unmeasured confounding variable cannot be ruled out. There were discrete 
differences in the medications used in each of the groups, but we adjusted for this 
variable in the multivariable analysis, and we consider that it did not impact the 
results obtained. All this shows that it would be advisable to confirm its results 
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through randomized clinical trials. As happens in any integrate care program 
(composed of various interventions administered simultaneously) it is not possible 
to determine which of the interventions of the CICP is responsible of the 
differences in the outcomes. 
In conclusion, in this historical cohort study, patients included in CICP had about 
50% fewer visits to emergency department and hospitalization for severe 
exacerbations during one year of follow-up compared to GCP patients in the same 
institution. These results justify a randomized clinical trial to confirm them. 
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Table 1. Characteristic of patients 
 
Values presented as means ± standard deviations or n (%)  
Categorical variables were assessed using Chi square or Fisher test in case of low frequencies. 
Categorical or quantitative variables that were associated with P<0.2 were introduced in the 
saturated multivariable model. 
*BMI: Body Mass Index  
**Classification of severity according to the Colombian Guide to Clinical Practice in COPD(20)  
***Severity of functional compromise: categorization of FEV1pos%. Mild >80%, moderate 50-80%, 
severe 30-49% and very severe <30%.  
 
 
 
 
Characteristic CICP group GCP group p value 
Age, years  76 ±9 77±10 0.32 
Males 89 (53.6) 97 (64.7) 0.46 
BMI*  25.64±4.6 26.79±5.5 0.045 
Exposure to tobacco 126 (84) 84 (67.7) 0.002 
Exposition to wood smoke 48 (28.9) 51 (43.6) 0.011 
Active smoking 16 (9.6) 10 (7.2) 0.45 
Classification of COPD severity**  
Mild   4 (2.4) 2 (1.3) 0.68 
Moderate   56 (36.7) 95 (63.3) <0.001 
Severe   75 (45.2) 34 (22.7) <0.001 
Very severe   31 (18.7) 19 (12.7) 0.14 
Severity of functional compromise***  
Mild   11 (7.1) 13 (10.1) 0.27 
Moderate   98 (63.2) 86 (66.7) 0.89 
Severe   37 (23.9) 26 (20.2) 0.83 
Very severe   9 (5.8) 4 (3.1) 0.97 
Post-bronchodilator FEV1- % 
predicted,   
58±16 62±20  
Post-bronchodilator FEV1/FVC   49.84±13 55.65±14.2 <0.001 
6-minute walk test, meters   407±134 404±111 0.86 
Comorbidities   
Arterial hypertension   89 (53.6) 85 (56.7) 0.58 
Type 2-Diabetes Mellitus   25 (15.1) 18 (12) 0.42 
Coronary Heart Disease   23 (13.9) 21 (14) 0.97 
Thromboembolic Disease   10 (6) 4 (2.7) 0.14 
Congestive Heart Failure   9 (5.4) 20 (13.3) 0.015 
Sleep Apnea   50 (30.1) 37 (24.7) 0.27 
Cancer   17 (10.2) 11 (7.3) 0.36 
Treatment     
Long Term Oxygen Therapy 119 (71.7) 124 (83.2) 0.015 
Pulmonary Rehabilitation   47 (28.3) 35 (23.3) 0.31 
Short-acting Bronchodilators  82 (49.4) 76 (50.7) 0.82 
Long-acting Bronchodilators  157 (94.6) 122 (81.3) <0.001 
Inhaled Steroids   100 (60.2) 90 (60) 0.96 
Roflumilast   5 (3) 3 (2) 0.72 
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 Table 2. Frequency of exacerbations by program 
 PROGRAM 
 CICP GCP 
No. Median IQR No. Median IQR 
Number of mild exacerbations 34 0 0 - 0 50 0 0 - 1 
Number of moderate exacerbations 91 0 0 - 1 26 0 0 - 0 
Number of severe exacerbations  56 0 0 - 0 64 0 0 - 1 
Number of mild plus moderate exacerbations 125 0 0 - 1 76 0 0 - 1 
Number exacerbations (Total) 181 1 0 - 2 140 0 0 - 1 
 
Note: CICP: COPD integrated care program; GCP: general consultation of pulmonology; No.: 
number; IQR: interquartile range (percentile 25  ̶ percentile 75). Follow-up time: 1 year for all 
patients. 
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Table 3. Incidence rate and incidence rate ratio of severe exacerbations per model 
of care 
Dependent Variable CICP GCP Adjusted IRR 
(multivariable model) 
 
 IR  IR  IRR (IC 95%) p value 
Visits to emergency department 9.7 20.7 0.47 (0.26-0.85) 0.012 
Hospitalizations 17.5 20.7 0.85 (0.52-1.39) 0.510 
Severe exacerbations 21.4 42.7 0.50 (0.29-0.87) 0.014 
Moderate exacerbations 63.3 17.3 3.65 (1.46-9.14) 0.006 
Mild exacerbations 14.5 33.3 0.44 (0.27-0.70) 0.001 
Mild plus moderate exacerbations 65.4 50.7 1.29 (0.92-1.73) 0.089 
 
 
CICP: COPD integrated care program 
IR: incidence rate (adjusted rates); IRR: incidence rate ratio (adjusted IRR) 
*The 316 patients are in the model shown. Estimates for incidence rate in the multivariable analysis 
were obtained by a Poisson regression model. IC stands for confidence interval. 
The IR for each group were the number of events (emergency services visits, hospitalization, 
severe, moderate or mild exacerbations) per 100 person-years. Follow-up time: 1 year for all 
patients. 
 
